Trial · NCT01183884
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma
NCT01183884, Phase 2, Terminated, Memorial Sloan Kettering Cancer Center; results first posted 2019-11-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma. Trials, record NCT01183884. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01183884
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma
- NCT number
- NCT01183884
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 46 participants, actual
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- Neuroblastoma
- Interventions
- 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid
- First posted
- 2010-08-18
- Last updated
- 2019-11-14
- Results first posted
- 2019-11-14
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Assess the Impact of High-dose 3F8/GM-CSF on Relapse-free Survival | 2 years | in patients in second or greater complete or very good partial remission, but at high risk of additional relapse. |
| Secondary | Apply Real-time Quantitative RT-PCR to Test the Hypothesis That the Minimal Residual Disease Content of Bone Marrow | 2 years | after the first treatments with 3F8/GMCSF has significant prognostic impact on relapse-free survival. |
| Secondary | Monitor Safety of the High-dose Antibody Treatment | 2 years | to assure no side-effects or noxious sequelae develop or emerge that were not seen in the prior phase I study. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Assess the Impact of High-dose 3F8/GM-CSF on Relapse-free Survival | 2 years | Data not collected | ||
| SECONDARY | Apply Real-time Quantitative RT-PCR to Test the Hypothesis That the Minimal Residual Disease Content of Bone Marrow | 2 years | Data not collected | ||
| SECONDARY | Monitor Safety of the High-dose Antibody Treatment | 2 years | Data not collected |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid | 46 | |
| Overall Study | COMPLETED | 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid | 8 | |
| Overall Study | NOT COMPLETED | 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid | 38 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid | 24 | 46 |
| Total, other adverse events | 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid | 0 | 0 |
| Total, serious adverse events | 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid | 0 | 0 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 23633099 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01183884
GET https://conductscience.org/api/trials/v1/NCT01183884/registered